デフォルト表紙
市場調査レポート
商品コード
1514197

膵臓がん治療薬の世界市場

Pancreatic Cancer Drugs

出版日
ページ情報
英文 151 Pages
納期
即日から翌営業日
適宜更新あり
膵臓がん治療薬の世界市場
出版日: 2024年07月17日
発行: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
ページ情報: 英文 151 Pages
納期: 即日から翌営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

膵臓がん治療薬の世界市場は2030年までに37億米ドルに到達

2023年に27億米ドルと推定される膵臓がん治療薬の世界市場は、2023～2030年の分析期間においてCAGR 4.7%で成長し、2030年には37億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである外分泌薬は、CAGR 4.9%を記録し、分析期間終了時には32億米ドルに達すると予測されます。内分泌薬セグメントは、分析期間中CAGR 3.4％で成長すると推定されます。

米国市場は7億1,780万米ドルと推定、中国はCAGR 8.0％で成長予測

米国の膵臓がん治療薬市場は2023年に7億1,780万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに7億9,100万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは8.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4%と5.2%と予測されています。欧州では、ドイツがCAGR 2.4%で成長すると予測されています。

膵臓がん治療薬-主要動向と促進要因

膵臓がんは、一般的に診断が遅く、膵臓自体が複雑な性質を持つことから、最も攻撃的で治療が困難ながんの1つです。膵臓は腹部の奥深くに位置し、消化とホルモン調節に重要な役割を果たしているため、外科的介入は危険で複雑なものとなります。その結果、膵臓がん治療薬の研究開発と進化は、腫瘍学研究の焦点となっています。これらの薬剤は、周囲の健康な組織へのダメージを最小限に抑えながら、がん細胞を特異的に標的とすることを目的としています。治療は伝統的な化学療法剤から最先端の標的療法や免疫療法まで多岐にわたり、それぞれが患者の生存率とQOLの向上を目指しています。膵臓がん治療薬に関する医薬品の状況はダイナミックであり、新たな作用機序や有効性を高めるための薬剤の組み合わせについて、数多くの臨床試験が進行中です。

バイオテクノロジーと分子生物学の最近の動向は、膵臓がん治療薬の開発に大きな影響を与えています。膵臓がんに関与する特定の遺伝子変異や分子経路に焦点を当てた標的療法が臨床試験で有望視されています。例えば、膵臓がんの多くの症例に見られるKRAS変異を標的とした薬剤が盛んに研究されています。さらに、身体の免疫系を利用してがんと闘う免疫療法も、膵臓がんの治療に可能性を示し始めています。免疫チェックポイント阻害剤であるペムブロリズマブのような治療薬が承認されたことで、特に特定の遺伝子プロファイルを持つ患者に対する治療の新たな道が開かれました。さらに、プレシジョン・メディシンの進歩により、より個別化された治療計画が可能になり、各患者のがんの特性に合わせた治療により治療成績が向上しています。

膵臓がん治療薬市場の成長は、技術革新や治療パラダイムの進化など、いくつかの要因によってもたらされます。人口の高齢化やライフスタイルの影響もあり、膵臓がんの有病率が増加していることから、より効果的な治療に対する需要が高まっています。ゲノム・プロファイリングとバイオマーカー同定の治療法の進歩により、特定のがん細胞メカニズムを標的とする薬剤の開発が可能になり、より効果的で毒性の低い治療法の選択肢が生まれています。また、複数の薬剤を使用してがん細胞をさまざまな面から攻撃する併用療法の台頭も、膵臓がんの管理に有益であることが証明されています。さらに、製薬会社による研究開発への多額の投資や、がん研究に対する政府からの助成金や資金援助があることも、市場の成長を後押ししています。画期的な治療法に対する規制当局の支援と承認プロセスの迅速化が市場をさらに牽引し、革新的な治療法がより迅速に患者に届くことを保証しています。認知度の向上と早期発見プログラムも、治療可能な段階で診断される患者数を増加させるため、市場拡大に寄与しています。これらの要因が相まって、膵臓がんと闘う患者に新たな希望をもたらす、強固で進化する市場環境が形成されています。

調査対象企業の例（全14件）

  • Amgen, Inc.
  • Celgene Corporation
  • Clovis Oncology
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • PharmaCyte Biotech, Inc.
  • Teva Pharmaceutical Industries Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6317

Global Pancreatic Cancer Drugs Market to Reach US$3.7 Billion by 2030

The global market for Pancreatic Cancer Drugs estimated at US$2.7 Billion in the year 2023, is expected to reach US$3.7 Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2023-2030. Exocrine Drugs, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$3.2 Billion by the end of the analysis period. Growth in the Endocrine Drugs segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$717.8 Million While China is Forecast to Grow at 8.0% CAGR

The Pancreatic Cancer Drugs market in the U.S. is estimated at US$717.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$791.0 Million by the year 2030 trailing a CAGR of 8.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Pancreatic Cancer Drugs - Key Trends and Drivers

Pancreatic cancer is one of the most aggressive and challenging types of cancer to treat, primarily due to its typically late diagnosis and the complex nature of the pancreas itself. The pancreas, situated deep within the abdomen, plays a crucial role in digestion and hormone regulation, making surgical interventions risky and complicated. Consequently, the development and evolution of pancreatic cancer drugs have become a focal point in oncology research. These drugs aim to target cancer cells specifically while minimizing damage to surrounding healthy tissues. Treatments range from traditional chemotherapy agents to cutting-edge targeted therapies and immunotherapies, each aiming to improve survival rates and quality of life for patients. The pharmaceutical landscape for pancreatic cancer drugs is dynamic, with numerous clinical trials underway exploring new mechanisms of action and drug combinations to enhance efficacy.

Recent advancements in biotechnology and molecular biology have significantly impacted the development of pancreatic cancer drugs. Targeted therapies that focus on specific genetic mutations and molecular pathways involved in pancreatic cancer have shown promise in clinical trials. For instance, drugs targeting the KRAS mutation, which is prevalent in a large percentage of pancreatic cancer cases, are being intensely studied. Additionally, immunotherapies, which harness the body’s immune system to fight cancer, have begun to show potential in treating pancreatic cancer. The approval of drugs like pembrolizumab, an immune checkpoint inhibitor, has opened new avenues for treatment, particularly for patients with specific genetic profiles. Furthermore, advancements in precision medicine allow for more personalized treatment plans, improving outcomes by tailoring therapies to the individual characteristics of each patient’s cancer.

The growth in the pancreatic cancer drugs market is driven by several factors, including technological innovations and evolving treatment paradigms. The increasing prevalence of pancreatic cancer, partly due to aging populations and lifestyle factors, has heightened the demand for more effective treatments. Advances in genomic profiling and biomarker identification have enabled the development of drugs that target specific cancer cell mechanisms, leading to more effective and less toxic treatment options. The rise of combination therapies, which use multiple drugs to attack cancer cells on different fronts, has also proven beneficial in managing pancreatic cancer. Moreover, substantial investments in research and development by pharmaceutical companies and the availability of government grants and funding for cancer research are propelling market growth. Regulatory support and accelerated approval processes for breakthrough therapies further drive the market, ensuring that innovative treatments reach patients more swiftly. Enhanced awareness and early detection programs are also contributing to market expansion, as they increase the number of patients diagnosed at treatable stages of the disease. Together, these factors create a robust and evolving market landscape, promising new hope for patients battling pancreatic cancer.

Select Competitors (Total 14 Featured) -

  • Amgen, Inc.
  • Celgene Corporation
  • Clovis Oncology
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • PharmaCyte Biotech, Inc.
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Pancreatic Cancer Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Pancreatic Cancer Expands Addressable Market Opportunity
    • Advancements in Genomic Profiling Propel Growth of Personalized Medicine Approaches
    • Emerging Immunotherapies Generate Demand for Innovative Treatment Options
    • Development of Targeted Therapies Strengthens Business Case for Precision Oncology
    • Growing Awareness and Early Detection Programs Spur Market Growth
    • Combination Therapies Enhance Treatment Efficacy
    • Adoption of Biomarker-Based Treatments Expands Addressable Market
    • Technological Innovations in Drug Delivery Systems Generate New Market Opportunities
    • Rising Prevalence of Lifestyle-Related Risk Factors Expands Market Potential
    • Advances in Artificial Intelligence and Machine Learning Accelerate Drug Discovery and Development
    • Economic Burden of Pancreatic Cancer Drives Demand for Cost-Effective Therapies
    • Increasing Focus on Quality of Life Issues Propels Growth of Supportive Care Medications
    • Integration of Telemedicine in Oncology Care Drives Adoption of Remote Treatment Solutions
    • Expanding Geriatric Population Impacts the Pancreatic Cancer Drugs Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Pancreatic Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Pancreatic Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Pancreatic Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Exocrine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Exocrine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Exocrine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Endocrine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Endocrine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Endocrine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Biologic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Biologic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Biologic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • JAPAN
    • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • CHINA
    • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • EUROPE
    • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Pancreatic Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Pancreatic Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • FRANCE
    • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • GERMANY
    • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Pancreatic Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Pancreatic Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • INDIA
    • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: India 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Pancreatic Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Pancreatic Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Pancreatic Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Pancreatic Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • AFRICA
    • Pancreatic Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Pancreatic Cancer Drugs by Type - Exocrine and Endocrine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Pancreatic Cancer Drugs by Type - Percentage Breakdown of Value Sales for Exocrine and Endocrine for the Years 2014, 2024 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Pancreatic Cancer Drugs by Therapy - Biologic, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Pancreatic Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Biologic, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030

IV. COMPETITION